Search Within

Department of Medicine

Formats
  1. Journal Article (19590)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (608)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22319)
  2. Hematologic Malignancies, Division of (13276)
  3. Center for Hematologic Malignancies (11060)
  4. GSK Faculty (10645)
  5. Survivorship Research (9329)
  6. Division of Subspecialty Medicine (7534)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1066)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2110)

More Publishers

Results (39617)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term follow up of a prospective pilot study of an α/β T-lymphocyte depleted graft conditioned with a reduced intensity regimen in patients with hematologic malignancies
    Meeting Abstract

    Hughes, C. F. M.; Lin, R. J.; Devlin, S. M.; Shaffer, B. C.; Jakubowski, A. A.; Talla, V.; Saldia, A.; Gyurkocza, B.; Papadopoulos, E. B.; Giralt, S. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Fixed-duration epcoritamab + R(2) drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the EPCORE NHL-2 trial
    Meeting Abstract

    Falchi, L.; Balari, A. S.; Leppä, S.; Vermaat, J. S. P.; Nijland, M.; Christensen, J. H.; de Vos, S.; Holte, H.; Merryman, R. W.; Lugtenburg, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Non-driver genomic alterations and venous thromboembolism in myeloproliferative neoplasms
    Meeting Abstract

    Ajufo, H.; Leader, A.; Derkach, A.; Chrysafi, P.; Singh, R.; Rampal, R.; Mantha, S.; Zwicker, J. I.
    Blood (2024)

    Fulltext@MSK | Save
  • Increased fiber intake results in better overall survival and lower GI-aGVHD in allo-HCT recipients and pre-clinical GVHD models
    Meeting Abstract

    Paredes, J.; Fei, T.; Dai, A.; Ramos, R.; Adintori, P.; Kousa, A.; Nguyen, C. L.; Victor, K.; Ghale, R.; Pohl, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • TMPRSS6 antisense oligonucleotide therapy reverses inflammation in Jak2(V617F) mutant mice
    Meeting Abstract

    Levy, M.; Li, H.; Dunbar, A.; Huang, Z.; Park, Y.; Lu, M.; Phattalung, P. N.; Planoutene, M.; Casu, C.; Rivella, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Mátrai, Z.; Sanna, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A CD33-deleted allograft (trem-cel) enables post-hematopoietic cell transplant (HCT) maintenance dosing of gemtuzumab ozogamicin (GO) with therapeutic levels of drug exposure and low hematologic and hepatic toxicity in patients with high-risk acute myeloid leukemia (AML)
    Meeting Abstract

    DiPersio, J. F.; Koehne, G.; Shah, N. N.; Bernard, L.; Suh, H. C.; Koura, D.; Perales, M. A.; Tamari, R.; Mushtaq, M. U.; Maakaron, J. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-cell atlas of diffuse large B-cell lymphoma reveals integrated malignant B cell and tumor microenvironment characteristics associated with clinical response
    Meeting Abstract

    Baaklini, S.; Sarrabay, A.; Mazuel, A.; Escaliere, B.; Dong, C.; Barthelemy, C.; Gil, L.; Dahbi, L.; Mossadegh-Keller, N.; Van Acker, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Fixed-duration epcoritamab in combination with bendamustine + rituximab for first-line treatment of follicular lymphoma: Initial results from EPCORE NHL-2 Arm 3
    Meeting Abstract

    Brody, J.; Falchi, L.; Vitolo, U.; Nijland, M.; Offner, F.; Snauwaert, S.; Patah, P.; Marek, J.; Morehouse, C.; Steele, A. J.; more...
    Blood (2024)

    Fulltext@MSK | Save